Therapeutic validation of an orphan G protein‐coupled receptor: The case of GPR84. (17th September 2020)

• Record Type: Journal Article
• Authors: Marsango, Sara; Barki, Natasja; Jenkins, Laura; Tobin, Andrew B.; Milligan, Graeme
• Other Names: Stephens Gary guestEditor.; Shukla Arun guestEditor.
• Is Part Of: British journal of pharmacology. Volume 179:Number 14(2022)
• Page Start: 3529
• Page End: 3541
• Publication Date: 2020-09-17
• Subjects: allosteric ligand -- GPCR -- GPR84 -- inflammation -- orphan receptor -- orthosteric ligand; Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15248
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Despite the importance of members of the GPCR superfamily as targets of a broad range of effective medicines many GPCRs remain poorly characterised. GPR84 is an example. Expression of GPR84 is strongly up regulated in immune cells in a range of pro‐inflammatory settings and clinical trials to treat idiopathic pulmonary fibrosis are currently ongoing using ligands with differing levels of selectivity and affinity as GPR84 antagonists. Although blockade of GPR84 may potentially prove effective also in diseases associated with inflammation of the lower gut there is emerging interest in defining if agonists of GPR84 might find utility in conditions in which regulation of metabolism or energy sensing is compromised. Here, we consider the physiological and pathological expression profile of GPR84 and, in the absence of direct structural information, recent developments and use of GPR84 pharmacological tool compounds to study its broader role and biology. LINKED ARTICLES: This article is part of a themed issue on Structure Guided Pharmacology of Membrane Proteins (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.14/issuetoc